Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients
Sun Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC.
(WRAL Tech Wire
Related: Campus Connections
Recent Campus Connections News:The Best Dive Bar In Every State (North Carolina) - He’s Not HereSaturday January 18, 2020Cooler on the Other Side: The Extraordinary Life and Legacy of Stuart ScottWednesday January 15, 2020New decade, same Sutton's: Patrons reminisce on legacy of a Tar Heel classicWednesday January 15, 2020Two UNC alumnae named recipients of Marshall ScholarshipWednesday January 15, 2020Mipso - The Unlikely Story Of A Band With A Lot To LikeSunday January 12, 2020